Effect Of Erigeron Injection On VEGF And SICAM-1 In Patients With Acute Cerebral Infarction About Syndrome Of Blood Stasis

Acute cerebral infarction, which is abbreviating ACI, is one of the severe cases in internal medicine. The major pathological basis of ACI is atherosclerosis, which take 80 percents. The angiemphraxis caused ischemic and anoxemia in the corresponding blood supply brain tissue. This formed centre zone of necrosis and ischemia semidarkness lane. Thus to improve the blood supply in the ischemia semidarkness lane is the key point in decreasing the infarct size. At the same time, how to lighten the inflammatory reaction is already one of the important steps in clinical treatment on ischemic cerebrovascular disease. ACI belongs to the stroke in traditional Chinese medicine. ACI is similar to acute cerebrovascular disease in modern medicine. From the endo-meridians on, a large quantity of physicians emphasize the important position of stagnant blood in the pathogenesis of stroke.This article takes it for granted that the core pathogenesis of the stroke is disharmonizing Qi and blood. The key point of the pathological changes is blood stasis. Thus the treatment method of activating blood circulation to dissipate blood stasis is the basic ones in treating the stroke. This study is based on the former investigation results and to move forward a single step for the variation rule of vascular endothelial growth factor (VEGF) and soluble intercellular adhesion molecule-1 (sICAM-1), in the patients of ACI with the syndrome of blood stasis. Then we observed the affection on VEGF and sICAM-1 in patients of ACI with the syndrome of blood stasis. All the results could provide guideline for clinical treatment on patients with ACI.Objective: To investigate the changes of Vascular Endothelial Growth Factor (VEGF), Soluble Intercellular Adhesion Molecule-1 (sICAM-1), symptom of neurologic impairment in patients with Acute Cerebral Infarction (ACI) of TCM syndrome of blood stasis with erigeron injection. To analyze the mechanism of erigeron injection on ACI, which provides the indexes for clinical treatment of ACI.Methods : According to the diagnosis standards and Chinese symptom standards, 60 patients with ACI were randomly divided into treated group (A group) and control group (B group), 30 cases of healthy elders were taken as normal control group (C group).The age, gender and integral of past diseases of all groups had no significant difference by statistic treatment. Patients of A group were treated with erigeron injection through intravenous drip, and the patients in B group used Fraxiparine by subcutaneous injection. The levels of blood serum VEGF, sICAM-1 were respectively measured before and after 14 days' treatment by enzyme- linked immunospecific assay and integral of syndrome of blood stasis and neurologic impairment were measured simultaneously.Results: 1. Compared the two groups' curative effect, the treatment group obviously surpassed control group (P<0. 05 = . 2. After treatment, the level of blood serums of VEGF, sICAM-1 changed significantly (P<0.01 = , but in the treated group, the VEGF increasing surpassed the control group (P<0. 01 = . Post-treatment there was no difference of the level of blood serums sICAM-1 between A group and B group. 3. The syndrome of blood stasis had improved (P<0.01 = , but the treated group got better (P<0.05 = . 4. There was significant positive correlation between the syndrome of blood stasis and sICAM-1 (r = 0.901, P<0.01 =, but the negative correlation with VEGF (r = -0.788, P <0.01).Conclusion: The levels of VEGF, sICAM-1 had close correlation with the syndrome of blood stasis. Erigeron injection can effectively reduce cerebral ischemic lesions, improve the cerebral blood circulation. It is effective and safe medicine for the acute stage of Cerebral Infarction.